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AIDS research must link to local policy

HIV research in South Africa is world class. To halt the country’s epidemic, scientists need to shift focus from global problems to priorities at home, say Salim Abdool Karim and Quarraisha Abdool Karim.

Despite being the continent’s scientific powerhouse, 16 years on from the end of apartheid South Africa has failed to make the most of its well-established clinical and research infrastructure and its rich tradition of scientific excellence in curbing the HIV epidemic. More than 1 out of every 10 South Africans are infected; 17% of the world’s HIV carriers are in South Africa, though it has only 0.7% of the world’s population; and the rates at which people are catching the virus and dying from AIDS are unacceptably high1. Nelson Mandela’s call at the XIII International AIDS conference in Durban a decade ago to “mobilise all of our resources and alliances … until this war is won” has too often fallen on stony ground.
The problem is not a lack of science. South African scientists have, for example, played leading roles in research on  the prevention of HIV transmission from mother to child2, the treatment of TB-HIV co-infection3,4, viral genetic diversity5 and the treatment of HIV-infected infants6,7. Furthermore, South African researchers are active participants in numerous international multi-centre clinical and laboratory studies on vaccines, microbicides, mother-to-child transmission, pre-exposure prophylaxis and a range of other approaches to prevent and treat HIV. What’s missing is an effective conduit between the country’s AIDS research and its prevention and treatment policies and programmes.
One of the main stumbling-blocks to achieving this is the lack of local research finance and the increasing reliance on foreign funding, which is largely channeled through independent agencies and geared towards providing sites and specimens for international AIDS studies. The step-up in international support has been dramatic: in 1990 the country was receiving negligible research funding from the US National Institutes of Health (NIH); by 2000 it was the largest recipient of NIH funds outside the USA. The dependence on international finance has shifted the focus of South Africa’s scientists from local to global priorities. For example, substantial research is being done in South Africa on developing HIV vaccines, yet little attention is being paid to devising new approaches to reduce high rates of infection among young women, the main driver of the HIV epidemic in the country.
	The disconnect between public health policy and research is rooted in the country’s recent history. When HIV emerged in apartheid South Africa in 1982, medical research in the country was focused on diseases of affluence rather than poverty; there was scant emphasis on public health. Until 1990, indigenous research provided little new data to guide efforts to prevent HIV on the ground and either inadvertently or deliberately portrayed HIV as a disease confined to gay men, black people or foreigners working in the mines. The first post-apartheid government prioritized AIDS in its Reconstruction and Development Programme, but it gave little political support to evidence-based interventions. The support for unorthodox AIDS denialist theories from President Thabo Mbeki and his health minister Manto Tshabalala-Msimang, along with their persistent attacks on science, put the government at odds with scientists, AIDS activists and the general public. By 2000 this schism had grown so deep that it was very difficult for scientists to influence the government’s AIDS control efforts. The distrust and antipathy simmered right up until last year’s change in government and the appointment of a new health minister.
Meanwhile domestic financing of AIDS research has stagnated. Government funding has been disproportionately low given the scale of the problem. At the time of the country’s first democratic elections in 1994, when 7.6% of pregnant women had HIV, government funding for AIDS research amounted to around $0.3 million (R2 million). A decade later, when HIV prevalence in pregnant women had increased nearly four-fold to 29.5%, it had grown only two and a half times, excluding funds raised through a newly created public-private partnership called the South African AIDS Vaccine Initiative (SAAVI). Meanwhile, thanks to contributions from international agencies, overall support for AIDS research grew 200 times during this period to an estimated $62.5 million (R400million).
	While South Africa’s AIDS strategy spent 20 years mired in disarray, its research community started to flourish. The transition to democracy ended decades-long academic isolation and re-opened links with the global scientific community. South African scientists rapidly established themselves as able to compete and collaborate with others across the world. The impact has been most evident in the dramatic increase in international funding for AIDS research. For example, in 1997 the Wellcome Trust provided a £5 million grant to create a rural research center on reproductive health, in 2000 the Doris Duke Charitable Foundation provided $5 million for an AIDS research institute, and recently the Howard Hughes Medical Institute announced an unprecedented contribution of $60 million towards the creation of an institute on tuberculosis and HIV.
	The unprecedented growth in funding from international sources during the first post-apartheid decade triggered a rapid expansion in AIDS research, training and physical infrastructure. This has had lasting benefits, for example leading to the establishment of 10 large independent AIDS research centers, which together account for close to 90% of the country’s expenditure on AIDS research. This level of financial autonomy has had three obvious benefits for the country’s research community. First, it has reduced dependence on the government, thus enabling scientists to challenge politicians on their AIDS denialism without fear of losing research funds. Second, it has raised the quality of local research to international standards. Third, it has enabled South Africa to build research capacity, for example through the Columbia University–Southern Africa Fogarty AIDS International Training and Research Program8. Over 15 years, this program has provided training for 310 young scientists, including 125 who obtained masters or doctoral degrees in the US and are now involved in almost every major AIDS research project in South Africa. Importantly, all of but two of the students who studied in the US returned to South Africa, an illustration of how international funding for AIDS science has provided some shelter from the damaging effects of the “brain drain”.
The flip-side to the foreign funding boom is that the direction of AIDS research in South Africa is increasingly influenced by the availability of external finance rather than local priorities. This is having a serious impact on the country’s efforts to deal with the epidemic. For instance, there has been little research on why the substantial increase in condom distribution in the country, rising from 8 million in 1994 to an estimated 376 million in 2006, has had  little impact on reducing HIV transmission, especially in high-risk sex between adult men and teenage girls. These failures are a marked departure from the significant impact medical researchers had on public health during the post-war period.
A new approach is needed to drive South African AIDS scientists to thwart HIV. There are four key steps. First, scientists and policy-makers must develop a common understanding of the main drivers and risk factors for HIV transmission at a local and country level. Researchers are still unclear over the relative importance of factors such as inter-generational sex and multiple partnerships. Data needs to be collated and synthesized so that researchers and policy-makers can agree on priorities. The fight against AIDS is likely to take decades and it’s important to understand the 
Second, regular interaction must occur between scientists, policy-makers and the leaders of public health programmes to ensure that AIDS policy takes account of the latest science. Up to now, politicians have not viewed science as critical to decision-making. Indeed, the government invests around R400 million each year – equivalent to the entire annual AIDS research expenditure – in advertising campaigns for unproven remedies. This has to change. A suitable forum for this is the South African National AIDS Council (SANAC), set up in 2000 to advise the government on HIV and AIDS policy and help oversee the national response to the epidemic.
Third, a national AIDS research agenda needs to be developed based on detailed knowledge of the country’s epidemic and the priorities for action. It needs to take a long-term view – AIDS is likely to be with us for decades – and should strike a balance between implementing and evaluating known effective public health strategies, and new technologies and approaches to prevention and treatment. Government backing will be essential and scientific excellence must remain the benchmark. South African researchers will have to re-direct some of their effort away from international agencies towards implementing this national agenda. A good example of a country that has developed an effective national AIDS agenda is Botswana. Driven by policy-makers at the highest level of government, it has created several public-private partnerships with the likes of Merck and the Gates Foundation and drawn up a clear set of priorities and targets for prevention and treatment.
Finally, government funding must increase substantially. Today, less than 5% of South Africa’s AIDS research funding comes from the government’s three major funding sources – the Medical Research Council, SAAVI and the newly established South African HIV/AIDS Research and Innovation Platform (SHARP). Even if the government increases its budget several-fold, international finance will still be required. Initiatives such as the NIH’s Comprehensive International Program of Research on AIDS (CIPRA), which supported globally relevant research in poorer countries, will be crucial.
The change in government leadership in 2009 has created new hope that the country will beat the HIV epidemic. Tailoring research to local needs is the most effective way to do that. South African science need not relinquish its important role in the global effort against HIV. Local solutions are likely to be globally applicable and will have a marked influence on the global burden of disease. The country has the scientific capacity, the top-class laboratories and, notably, a newfound commitment by policy-makers, scientists and health service leaders to work together to finally take up the challenge Mandela proposed a decade ago. We cannot afford to fail.
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